Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial

Drug and Alcohol Dependence

Volumn 156, Issue , 2015, Pages 29-37

  McRae Clark, Aimee L ^a   Baker, Nathaniel L ^a   Gray, Kevin M ^a   Killeen, Therese K ^a   Wagner, Amanda M ^a   Brady, Kathleen T ^a   DeVane, C Lindsay ^a   Norton, Jessica ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Buspirone; Cannabis; Contingency management; Gender differences; Motivational enhancement therapy

Indexed keywords

BUSPIRONE; CANNABINOID; CREATININE; PLACEBO; SEROTONIN 1A RECEPTOR; SEROTONIN AGONIST;

ADULT; ARTICLE; BLOOD LEVEL; CANNABIS ADDICTION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; URINALYSIS; YOUNG ADULT; ALLELE; BLOOD; DOUBLE BLIND PROCEDURE; GENETICS; MARIJUANA ABUSE; MOTIVATION; MULTIMODALITY CANCER THERAPY; PSYCHOLOGY; PSYCHOTHERAPY; SEXUAL DEVELOPMENT; TREATMENT OUTCOME;

ADULT; ALLELES; BUSPIRONE; CANNABINOIDS; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; MOTIVATION; PATIENT COMPLIANCE; PSYCHOTHERAPY; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN RECEPTOR AGONISTS; SEX CHARACTERISTICS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84946498183     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2015.08.013     Document Type: Article

References (52)

1. Anthony J.C., Helzer J.E. Syndromes of drug abuse and dependence. Psychiatric Disorders in America 1991, 116-154. Free Press, New York. L.N. Robins, D.A. Reiger (Eds.).
2. Anthony J.C., Warner L.A., Kessler R.C. Comparative epidemiology of dependence on tobacco, controlled substances, and inhalants: basic findings from the National Comorbidity Study. Exp. Clin. Psychopharmacol. 1994, 2:244-268.
3. Boldrini M., Underwood M.D., Mann J.J., Arango V. Serotonin-1A autoreceptor binding in the dorsal raphe nucleus of depressed suicides. J. Psychiatr. Res. 2008, 42:433-442.
4. Buckner J.D., Bonn-Miller M.O., Zvolensky M.J., Schmidt N.B. Marijuana use and social anxiety among marijuana using young adults. Addict. Behav. 2007, 32:2238-2252.
5. Buckner J.D., Carroll K.M. Effect of anxiety on treatment presentation and outcome: results from the Marijuana Treatment Project. Psychiatry Res. 2010, 178:493-500.
6. Budney A.J., Novy P.L., Hughes J.R. Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction 1999, 94:1311-1321.
7. Carpenter K.M., McDowell D., Brooks D.J., Cheng W.Y., Levin F.R. A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. Am. J. Addict. 2009, 18:53-64.
8. Carroll K.M., Kosten T.R., Rounsaville B.J. Choosing a behavioral therapy platform for pharmacotherapy of substance users. Drug Alcohol Depend. 2004, 75:123-134.
9. Compton W.M., Pringle B. Services research on adolescent drug treatment. Commentary on "The Cannabis Youth Treatment (CYT) Study: main findings from two randomized trials". J. Subst. Abuse Treat. 2004, 27:195-196.
10. Darmani N.A., Janoyan J.J., Kumar N., Crim J.L. Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover. Pharmacol. Biochem. Behav. 2003, 75:777-787.
11. David S.P., Johnstone E.C., Murphy M.F., Aveyard P., Guo B., Lerman C., Munafo M.R. Genetic variation in the serotonin pathway and smoking cessation with nicotine replacement therapy: new data from the Patch in Practice trial and pooled analyses. Drug Alcohol Depend. 2008, 98:77-85.
12. Drevets W.C., Thase M.E., Moses-Kolko E.L., Price J., Frank E., Kupfer D.J., Mathis C. Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl. Med. Biol. 2007, 34:865-877.
13. Eskridge K.D., Guthrie S.K. Clinical issues associated with urine testing of substances of abuse. Pharmacotherapy 1997, 17:497-519.
14. Fernandez-Guasti A., Picazo O. The actions of diazepam and serotonergic anxiolytics vary according to the gender and the estrous cycle phase. Pharmacol. Biochem. Behav. 1990, 37:77-81.
15. Fernandez-Guasti A., Picazo O. Anxiolytic actions of diazepam, but not of buspirone, are influenced by gender and the endocrine stage. Behav. Brain Res. 1997, 88:213-218.
16. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P) 2002, Biometrics Research, New York State Institute, New York.
17. Goa K.L., Ward A. Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 1986, 32:114-129.
18. Gomes F.V., Resstel L.B., Guimaraes F.S. The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors. Psychopharmacology (Berl.) 2011, 213:465-473.
19. Gray K.M., Carpenter M.J., Baker N.L., DeSantis S.M., Kryway E., Hartwell K.J., McRae-Clark A.L., Brady K.T. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am. J. Psychiatry 2012, 169:805-812.
20. Gray K.M., Carpenter M.J., Baker N.L., Hartwell K.J., Lewis A.L., Hiott D.W., Deas D., Upadhyaya H.U. Buproprion SR and contingency management for adolescent smoking cessation. J. Subst. Abuse Treat. 2011, 40:77-86.
21. Hamilton M. The assessment of anxiety states by rating. Br. J. Psychiatry 1959, 32:50-55.
22. Heishman S.J., Evans R.J., Singleton E.G., Levin K.H., Copersino M.L., Gorelick D.A. Reliability and validity of a short form of the Marijuana Craving Questionnaire. Drug Alcohol Depend. 2009, 102:35-40.
23. Hill M.N., Sun J.C., Tse M.T., Gorzalka B.B. Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment. Int. J. Neuropsychopharmacol. 2006, 9:277-286.
24. Huestis M.A., Cone E.J. Differentiating new marijuana use from residual drug excretion in occasional marijuana users. J. Anal. Toxicol. 1998, 22:445-454.
25. Jovanovic H., Lundberg J., Karlsson P., Cerin A., Saijo T., Varrone A., Halldin C., Nordstrom A.-L. Sex differences in the serotonin 1A receptor and serotonin transporter binding in the human brain measured by PET. NeuroImage 2008, 39:1408-1419.
26. Kadden R.M., Litt M.D., Kabela-Cormier E., Petry N.M. Abstinence rates following behavioral treatments for marijuana dependence. Addict. Behav. 2007, 32:1220-1236.
27. Lader M. Can buspirone induce rebound, dependence or abuse?. Br. J. Psychiatry Suppl. 1991, 12:45-51.
28. Le Francois B., Czesak M., Steubl D., Albert P.R. Transcriptional regulation at a HTR1A polymorphism associated with mental illness. Neuropharmacology 2008, 55:977-985.
29. Lemonde S., Turecki G., Bakish D., Du L., Hrdina P.D., Bown C.D., Sequeira A., Kushwaha N., Morris S.J., Basak A., Ou X.M., Albert P.R. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J. Neurosci. 2003, 23:8788-8799.
30. Levin F.R., Mariani J.J., Brooks D.J., Pavlicova M., Cheng W., Nunes E.V. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2011, 116:142-150.
31. Marshall K., Gowing L., Ali R., Le Foll B. Pharmacotherapies for cannabis dependence. Cochrane Database System. Rev. 2014, 12:1-64.
32. Mason B.J., Crean R., Goodell V., Light J.M., Quello S., Shadan F., Buffkins K., Kyle M., Adusumalli M., Begovic A., Rao S. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology 2012, 37:1689-1698.
33. Mato S., Vidal R., Castro E., Diaz A., Pazos A., Valdizan E.M. Long-term fluoxetine treatment modulates cannabinoid type 1 receptor-mediated inhibition of adenylyl cyclase in the rat prefrontal cortex through 5-hydroxytryptamine 1A receptor-dependent mechanisms. Mol. Pharmacol. 2010, 77:424-434.
34. McRae A.L., Budney A.J., Brady K.T. Treatment of marijuana dependence: a review of the literature. J. Subst. Abuse Treat. 2003, 24:369-376.
35. McRae-Clark A.L., Carter R.E., Killeen T.K., Carpenter M.J., Wahlquist A.E., Simpson S.A., Brady K.T. A placebo-controlled trial of buspirone for the treatment of marijuana dependence. Drug Alcohol Depend. 2009, 105:7.
36. McRae-Clark A.L., Carter R.E., Killeen T.K., Carpenter M.J., White K.G., Brady K.T. A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder. Am. J. Addict. 2010, 19:481-489.
37. Nakazi M., Bauer U., Nickel T., Kathmann M., Schlicker E. Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Naunyn Schmiedebergs Arch. Pharmacol. 2000, 361:19-24.
38. Nordstrom B.R., Levin F.R. Treatment of cannabis use disorders: a review of the literature. Am. J. Addict. 2007, 16:331-342.
39. Pan W. Akaike's information criterion in generalized estimating equations. Biometrics 2001, 57:120-125.
40. Poling J., Oliveto A., Petry N., Sofuoglu M., Gonsai K., Gonzalez G., Martell B., Kosten T.R. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch. Gen. Psychiatry 2006, 63:219-228.
41. SAMHSA National Household Survey on Drug Use and Health 2014, SAMHSA, Rockville.
42. Schmitz J.M., Mooney M.E., Moeller F.G., Stotts A.L., Green C., Grabowski J. Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform. Drug Alcohol Depend. 2008, 94:142-150.
43. Sobell L.C., Sobell M.B. Timeline follow-back: a technique for assessing self-reported ethanol consumption. Measuring Alcohol Consumption: Psychological And Biological Methods 1992, 41-72. Humana Press, Totowa, NJ. J. Allen, R.Z. Litten (Eds.).
44. Steinberg K.L., Roffman R.A., Carroll K.M., McRee B., Babor T.F., Miller M., Kadden R., Duresky D., Stephens R. Brief Counseling for Marijuana Dependence: A Manual for Treating Adults (Vol. HHS Publication No. (SMA) 12-4211) 2005, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, Rockville.
45. Stinson F.S., Ruan W.J., Pickering R., Grant B.F. Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. Psychol. Med. 2006, 36:1447-1460.
46. Stout R.L., Wirtz P.W., Carbonari J.P., Del Boca F.K. Ensuring balanced distribution of prognostic factors in treatment outcome research. J. Stud. Alcohol Suppl. 1994, 12:70-75.
47. Vandrey R., Haney M. Pharmacotherapy for cannabis dependence: how close are we?. CNS Drugs 2009, 23:543-553.
48. Weinstein A.M., Miller H., Bluvstein I., Rapoport E., Schreiber S., Bar-Hamburger R., Bloch M. Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study. Am. J. Drug Alcohol Abuse 2014, 40:16-22.
49. Winhusen T.M., Kropp F., Lindblad R., Douaihy A., Haynes L., Hodgkins C., Chartier K., Kampman K.M., Sharma G., Lewis D.F., VanVeldhuisen P., Theobald J., May J., Brigham G.S. Multisite, randomized, double-blind, placebo-controlled pilot clinical trial to evaluate the efficacy of buspirone as a relapse-prevention treatment for cocaine dependence. J. Clin. Psychiatry 2014, 75:757-764.
50. Zanelati T.V., Biojone C., Moreira F.A., Guimaraes F.S., Joca S.R. Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br. J. Pharmacol. 2010, 159:122-128.
51. Zeger S.L., Liang K.Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986, 42:121-130.
52. Zvolensky M.J., Marshall E.C., Johnson K., Hogan J., Bernstein A., Bonn-Miller M.O. Relations between anxiety sensitivity, distress tolerance, and fear reactivity to bodily sensations to coping and conformity use motives among young adult marijuana users. Exp. Clin. Psychopharmacol. 2009, 17:31-42.